[
    [
        {
            "time": "2018-03-15",
            "original_text": "Mallinckrodt Gets FDA Committee Vote for Abuse-Deterrent Drug",
            "features": {
                "keywords": [
                    "Mallinckrodt",
                    "FDA",
                    "Committee",
                    "Vote",
                    "Abuse-Deterrent",
                    "Drug"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Mallinckrodt Gets FDA Committee Vote for Abuse-Deterrent Drug",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-20",
            "original_text": "Exploring Clovis Oncology’s Operational Performance",
            "features": {
                "keywords": [
                    "Clovis",
                    "Oncology",
                    "Operational",
                    "Performance"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Exploring Clovis Oncology’s Operational Performance",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-05-10",
            "original_text": "Understanding Clovis Oncology’s Gross Margin Trend",
            "features": {
                "keywords": [
                    "Clovis",
                    "Oncology",
                    "Gross",
                    "Margin",
                    "Trend"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Understanding Clovis Oncology’s Gross Margin Trend",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-06-05",
            "original_text": "Lilly Offers Updates on Progress of Headache Disorder Drugs",
            "features": {
                "keywords": [
                    "Lilly",
                    "Updates",
                    "Progress",
                    "Headache",
                    "Disorder",
                    "Drugs"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Lilly Offers Updates on Progress of Headache Disorder Drugs",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-07-12",
            "original_text": "Exelixis, Ipsen Get EU Nod for Label Expansion of Cabometyx",
            "features": {
                "keywords": [
                    "Exelixis",
                    "Ipsen",
                    "EU",
                    "Nod",
                    "Label",
                    "Expansion",
                    "Cabometyx"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Exelixis, Ipsen Get EU Nod for Label Expansion of Cabometyx",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]